BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $166,800 | -96.0% | 20,000 | -94.6% | 0.01% | -96.3% |
| Q4 2022 | $4,216,604 | -24.3% | 367,300 | -16.9% | 0.37% | -31.5% |
| Q3 2022 | $5,568,000 | +19.1% | 441,900 | 0.0% | 0.55% | +28.5% |
| Q2 2022 | $4,675,000 | -35.2% | 441,900 | -0.3% | 0.42% | -24.4% |
| Q1 2022 | $7,210,000 | +15.7% | 443,400 | -1.4% | 0.56% | +28.9% |
| Q4 2021 | $6,230,000 | -2.1% | 449,800 | +1.6% | 0.44% | -15.7% |
| Q3 2021 | $6,364,000 | -7.8% | 442,900 | +1.4% | 0.52% | -5.7% |
| Q2 2021 | $6,904,000 | +55.8% | 436,690 | +0.2% | 0.55% | +31.1% |
| Q1 2021 | $4,432,000 | +98.2% | 435,790 | +45.2% | 0.42% | +79.4% |
| Q4 2020 | $2,236,000 | +272.0% | 300,190 | +71.5% | 0.23% | +228.2% |
| Q3 2020 | $601,000 | +214.7% | 175,000 | +337.5% | 0.07% | +184.0% |
| Q2 2020 | $191,000 | – | 40,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |